iLite Type I IFN FAST
iLite Type I IFN FAST are Developed and Manufactured by Svar Life Science
The Eagle Biosciences iLite Type I IFN FAST are intended for:
- Quantification of functional IFNβ
- Quantification of IFNβ inhibitor activity
- Quantification of functional IFNα
- Quantification of IFNα inhibitor activity
Content: >250 µL of Assay Ready Cells suspended in cryoprotective medium from Gibco.
Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C or at lower temperature and are stable as supplied until the expiry date shown. Cells should be diluted and plated immediately after thawing.
For Research Use Only
Key benefits of iLite Assays
- Highly specific reporter gene cell lines
- Very sensitive cell line responses (10 fold inductions)
- Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
- Assays within a workday (typically 4-7 hour assays)
- Normalization gene, which eliminates unwanted matrix effects
iLite® IFN type 1 FAST Assay Ready Cells are human embryonic kidney HEK2931 cells which have been genetically engineered and optimized to be responsive to type 1 interferon, resulting in a proportional expression of Firefly Luciferase. The cells also contain the Renilla Luciferase internal standardization gene under the control of a constitutive promoter that renders assay results independent of cell number and provides a means for correcting for cytotoxic effects that may be encountered with some biological samples.
Interferons (IFNs) are cytokines with antiviral, antitumor and immunoregulatory functions, released by both immune and nonimmune cells as a first line of host innate defense, particularly viral infections. IFNs are classified into three groups and generally initiate signaling via the JAK-STAT (Janus kinase/signal transducer and activator of transcription) pathway. Type I IFNs includes at least 16 different subtypes, most well defined are IFN alpha (IFNα) and IFN beta (IFNβ) which binds to the heterodimeric IFN alpha/beta receptor (IFNAR) thereby inducing intracellular signaling. Type I IFNs are used in several clinical settings, due to their antiviral and immunomodulatory properties. These properties have generated interest in their clinical use to enhance antigen presentation, control viral infections and promote antitumor responses. Recently, a robust type I interferon response has been observed in patients with severe COVID-19, which could contribute to the exacerbated hyperinflammation observed in the progression to severe COVID-19.